Abstract
OBJECTIVE: Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone. RESEARCH DESIGN AND METHODS: The study was conducted worldwide in 465 subjects, with baseline HbA1c of 7-10% (53-86 mmol/mol) and fasting serum glucose of 130-240 mg/dL, randomized to placebo versus ranolazine. RESULTS: Compared with placebo, there was a greater decline in HbA1c at week 24 from baseline (primary end point) in subjects taking ranolazine (mean difference -0.56% [-6.1 mmol/mol]; P <0.0001). Moreover, the proportion of subjects achieving an HbA1c 1c and other measures of glycemic control.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1189-1196 |
| Number of pages | 8 |
| Journal | Diabetes Care |
| Volume | 38 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Cite this
Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. / Eckel, Robert H.; Henry, Robert R.; Yue, Patrick; Dhalla, Arvinder; Wong, Pamela; Jochelson, Philip; Belardinelli, Luiz; Skyler, Jay S.
In: Diabetes Care, Vol. 38, No. 7, 01.07.2015, p. 1189-1196.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes
AU - Eckel, Robert H.
AU - Henry, Robert R.
AU - Yue, Patrick
AU - Dhalla, Arvinder
AU - Wong, Pamela
AU - Jochelson, Philip
AU - Belardinelli, Luiz
AU - Skyler, Jay S
PY - 2015/7/1
Y1 - 2015/7/1
N2 - OBJECTIVE: Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone. RESEARCH DESIGN AND METHODS: The study was conducted worldwide in 465 subjects, with baseline HbA1c of 7-10% (53-86 mmol/mol) and fasting serum glucose of 130-240 mg/dL, randomized to placebo versus ranolazine. RESULTS: Compared with placebo, there was a greater decline in HbA1c at week 24 from baseline (primary end point) in subjects taking ranolazine (mean difference -0.56% [-6.1 mmol/mol]; P <0.0001). Moreover, the proportion of subjects achieving an HbA1c 1c and other measures of glycemic control.
AB - OBJECTIVE: Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone. RESEARCH DESIGN AND METHODS: The study was conducted worldwide in 465 subjects, with baseline HbA1c of 7-10% (53-86 mmol/mol) and fasting serum glucose of 130-240 mg/dL, randomized to placebo versus ranolazine. RESULTS: Compared with placebo, there was a greater decline in HbA1c at week 24 from baseline (primary end point) in subjects taking ranolazine (mean difference -0.56% [-6.1 mmol/mol]; P <0.0001). Moreover, the proportion of subjects achieving an HbA1c 1c and other measures of glycemic control.
UR - http://www.scopus.com/inward/record.url?scp=84944356404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944356404&partnerID=8YFLogxK
U2 - 10.2337/dc14-2629
DO - 10.2337/dc14-2629
M3 - Article
C2 - 26049552
AN - SCOPUS:84944356404
VL - 38
SP - 1189
EP - 1196
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 7
ER -